Here are some ways lymphoma patients, survivors and caregivers can best navigate the internet for information, emotional and social support needs.
U.S. Food and Drug Administration Approves Ruxolitinib (Jakafi) for Chronic Graft-Versus-Host Disease
Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.
On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Survivor: Africa Winner, Humanitarian and Cancer Survivor Ethan Zohn Named an Official Ambassador for the Lymphoma Research Foundation
Zohn joins a national LRF Ambassador program in which individuals from around the country share their stories of hope. With more than 100 types of lymphoma, many LRF Ambassadors’ diagnoses are different.
Ask the Doctor: What is the difference between primary cutaneous, systemic, and breast-implant associated ALCL?
Milos Miljkovic, MD MSc of the National Cancer Institute Center for Cancer Research discusses the main differences between these types of ALCL, how they are diagnosed, and typical frontline therapies.
On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).
Krish Patel, MD of the Swedish Cancer Institute discusses how MRD is measured and what patients should know about testing for it.
Ask the Doctor: There are several therapies now approved for relapsed/refractory DLBCL. What is a good way to determine which are the best options for me?
LRF grantee Jason Romancik, MD of the Winship Cancer Institute discusses these treatment options and what factors patients should consider when deciding what's right for them.
LRF grantee Natalie Grover, MD of The University of North Carolina at Chapel Hill discusses the evolution of treatments in the past several years and the effect it has had on patients diagnosed with HL.
Ask the Doctor: Are there any oral therapies that are currently under investigation for frontline MCL?
LRF grantee Christina Lee, MD of the Memorial Sloan Kettering Cancer Center discusses the oral therapies that are currently under investigation for the treatment of frontline MCL and how this could help improve the treatment landscape for these patients.